FDA’s Patient-Focused Meetings: Round One Selections Include Diseases Broad And Rare
Breast and lung cancer, female sexual dysfunction and hemophilia are among 16 diseases that FDA will discuss with patients to get their perspective for drug development; additional diseases will be chosen in a future round.
You may also be interested in...
Drug reviews will include a benefit-risk summary assessment that states the rationale for regulatory action on a drug or biologic application and explains how differences of opinion among reviewers were resolved.
CDER’s Janet Woodcock says the community has the agency’s ear when it advocates new developments; cites need for an “adult conversation” in assessing when drugs should be made available to patients.
Two more Phase III studies for the hypoactive sexual desire disorder therapy is the firm’s best financial investment, CEO Simes says, because the revised design is expected to eliminate the greater-than-expected placebo response that derailed the previous studies.